Nepsis Inc. Acquires 90,852 Shares of Bristol Myers Squibb Company $BMY

Nepsis Inc. raised its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 49.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 274,149 shares of the biopharmaceutical company’s stock after buying an additional 90,852 shares during the quarter. Bristol Myers Squibb comprises 4.6% of Nepsis Inc.’s investment portfolio, making the stock its 11th largest position. Nepsis Inc.’s holdings in Bristol Myers Squibb were worth $14,788,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Darwin Wealth Management LLC purchased a new stake in Bristol Myers Squibb in the second quarter worth $25,000. Harbor Capital Advisors Inc. boosted its holdings in Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares in the last quarter. KERR FINANCIAL PLANNING Corp purchased a new position in Bristol Myers Squibb during the 3rd quarter valued at $35,000. JPL Wealth Management LLC bought a new position in Bristol Myers Squibb in the 3rd quarter worth $36,000. Finally, Total Investment Management Inc. purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth about $38,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Trading Down 1.4%

Shares of NYSE BMY opened at $58.59 on Friday. The firm’s 50 day moving average price is $58.82 and its 200-day moving average price is $52.20. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The company has a market cap of $119.62 billion, a PE ratio of 16.98, a P/E/G ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. Bristol Myers Squibb’s revenue was up 1.3% on a year-over-year basis. During the same period last year, the business earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BMY. Leerink Partners lifted their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Scotiabank restated a “sector perform” rating and issued a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Citigroup lifted their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Wells Fargo & Company reiterated an “outperform” rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Finally, Royal Bank Of Canada began coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 target price for the company. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $61.41.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.